Anti-CD20-IL-21 fusokine

The tail wags the dog

Research output: Contribution to journalComment/debate

Abstract

In this issue of Blood, Bhatt et al have shown that fusing interleukin 21 (IL-21) to an anti-CD20 antibody results in a molecule that has superior antilymphoma activity than each of its individual components.1 They find that the fused IL-21 induces direct cytotoxicity to the lymphoma cells but also activates immune effector cells that enhance the efficacy of the anti-CD20 antibody. The addition of IL-21 to an anti-CD20 antibody to form an anti-CD20-IL-21 fusokine therefore provides enhanced activity in 2 ways: firstly, it increases cytotoxicity directly targeting the malignant cell, and secondly, it modulates and augments the anti-tumor immune response (see figure).

Original languageEnglish (US)
Pages (from-to)2209-2210
Number of pages2
JournalBlood
Volume129
Issue number16
DOIs
StatePublished - Apr 20 2017

Fingerprint

Anti-Idiotypic Antibodies
Cytotoxicity
Antibodies
Tumors
Lymphoma
Blood
Molecules
interleukin-21
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Anti-CD20-IL-21 fusokine : The tail wags the dog. / Ansell, Stephen Maxted.

In: Blood, Vol. 129, No. 16, 20.04.2017, p. 2209-2210.

Research output: Contribution to journalComment/debate

Ansell, Stephen Maxted. / Anti-CD20-IL-21 fusokine : The tail wags the dog. In: Blood. 2017 ; Vol. 129, No. 16. pp. 2209-2210.
@article{fccbd124ef6c4f6087ff0498fc77d22b,
title = "Anti-CD20-IL-21 fusokine: The tail wags the dog",
abstract = "In this issue of Blood, Bhatt et al have shown that fusing interleukin 21 (IL-21) to an anti-CD20 antibody results in a molecule that has superior antilymphoma activity than each of its individual components.1 They find that the fused IL-21 induces direct cytotoxicity to the lymphoma cells but also activates immune effector cells that enhance the efficacy of the anti-CD20 antibody. The addition of IL-21 to an anti-CD20 antibody to form an anti-CD20-IL-21 fusokine therefore provides enhanced activity in 2 ways: firstly, it increases cytotoxicity directly targeting the malignant cell, and secondly, it modulates and augments the anti-tumor immune response (see figure).",
author = "Ansell, {Stephen Maxted}",
year = "2017",
month = "4",
day = "20",
doi = "10.1182/blood-2017-02-767541",
language = "English (US)",
volume = "129",
pages = "2209--2210",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Anti-CD20-IL-21 fusokine

T2 - The tail wags the dog

AU - Ansell, Stephen Maxted

PY - 2017/4/20

Y1 - 2017/4/20

N2 - In this issue of Blood, Bhatt et al have shown that fusing interleukin 21 (IL-21) to an anti-CD20 antibody results in a molecule that has superior antilymphoma activity than each of its individual components.1 They find that the fused IL-21 induces direct cytotoxicity to the lymphoma cells but also activates immune effector cells that enhance the efficacy of the anti-CD20 antibody. The addition of IL-21 to an anti-CD20 antibody to form an anti-CD20-IL-21 fusokine therefore provides enhanced activity in 2 ways: firstly, it increases cytotoxicity directly targeting the malignant cell, and secondly, it modulates and augments the anti-tumor immune response (see figure).

AB - In this issue of Blood, Bhatt et al have shown that fusing interleukin 21 (IL-21) to an anti-CD20 antibody results in a molecule that has superior antilymphoma activity than each of its individual components.1 They find that the fused IL-21 induces direct cytotoxicity to the lymphoma cells but also activates immune effector cells that enhance the efficacy of the anti-CD20 antibody. The addition of IL-21 to an anti-CD20 antibody to form an anti-CD20-IL-21 fusokine therefore provides enhanced activity in 2 ways: firstly, it increases cytotoxicity directly targeting the malignant cell, and secondly, it modulates and augments the anti-tumor immune response (see figure).

UR - http://www.scopus.com/inward/record.url?scp=85028307905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028307905&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-02-767541

DO - 10.1182/blood-2017-02-767541

M3 - Comment/debate

VL - 129

SP - 2209

EP - 2210

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -